First Mature Estimation of Median OS for Selpercatinib in Patients with RET Fusion-Positive NSCLC By Ogkologos - March 12, 2025 721 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from final efficacy and safety analyses from the LIBRETTO-001 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Indications for Serplulimab Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian Cancer Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma MOST POPULAR When Cancer Isn’t Your Only Challenge: How I Learned to Cope March 24, 2022 Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and... April 14, 2026 Fake Amazon Delivery Driver Attempts to Steal Elderly Woman’s Cancer Drugs February 19, 2020 EMA Recommends Extension of Therapeutic Indications for Rucaparib October 27, 2023 Load more HOT NEWS FDA Approves Selpercatinib for Locally Advanced or Metastatic RET Fusion-Positive Solid... 6 things you need to know about cervical screening EMA Recommends Granting a Conditional Marketing Authorisation for Selinexor A New Online Tool Predicts RFS and OS Probabilities in Patients...
